Brokers Set Expectations for IONS Q1 Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Stock analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Ionis Pharmaceuticals in a research note issued to investors on Wednesday, February 19th. William Blair analyst M. Minter expects that the company will post earnings per share of ($1.17) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. William Blair also issued estimates for Ionis Pharmaceuticals’ Q2 2026 earnings at ($1.07) EPS, Q3 2026 earnings at ($0.89) EPS and Q4 2026 earnings at ($0.85) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.46. The business had revenue of $227.00 million for the quarter, compared to the consensus estimate of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company’s revenue was down 30.2% on a year-over-year basis. During the same period last year, the business posted $0.12 EPS.

Several other equities research analysts also recently issued reports on IONS. Citigroup dropped their price objective on Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday, February 20th. BMO Capital Markets dropped their price objective on Ionis Pharmaceuticals from $60.00 to $45.00 and set a “market perform” rating on the stock in a report on Thursday, February 20th. Wells Fargo & Company dropped their price objective on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. Royal Bank of Canada restated an “outperform” rating and set a $70.00 price objective on shares of Ionis Pharmaceuticals in a report on Thursday, February 20th. Finally, Piper Sandler dropped their price objective on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Ionis Pharmaceuticals Stock Performance

Shares of NASDAQ:IONS opened at $31.89 on Monday. The company has a market cap of $5.07 billion, a P/E ratio of -10.49 and a beta of 0.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. Ionis Pharmaceuticals has a one year low of $30.23 and a one year high of $52.34. The business’s 50-day simple moving average is $33.52 and its 200 day simple moving average is $38.13.

Institutional Trading of Ionis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Signaturefd LLC raised its stake in shares of Ionis Pharmaceuticals by 160.0% in the 4th quarter. Signaturefd LLC now owns 949 shares of the company’s stock worth $33,000 after buying an additional 584 shares in the last quarter. Huntington National Bank raised its stake in shares of Ionis Pharmaceuticals by 193.5% in the 4th quarter. Huntington National Bank now owns 951 shares of the company’s stock worth $33,000 after buying an additional 627 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter worth $40,000. Lindbrook Capital LLC raised its stake in shares of Ionis Pharmaceuticals by 183.8% in the 4th quarter. Lindbrook Capital LLC now owns 1,036 shares of the company’s stock worth $36,000 after buying an additional 671 shares in the last quarter. Finally, Prospera Private Wealth LLC bought a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter worth $42,000. Institutional investors own 93.86% of the company’s stock.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 7,154 shares of the business’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.84, for a total transaction of $234,937.36. Following the completion of the transaction, the executive vice president now owns 45,670 shares in the company, valued at approximately $1,499,802.80. The trade was a 13.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Patrick R. O’neil sold 1,207 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $32.35, for a total value of $39,046.45. Following the transaction, the executive vice president now owns 56,245 shares of the company’s stock, valued at $1,819,525.75. This trade represents a 2.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 111,816 shares of company stock worth $3,603,914 in the last 90 days. 2.71% of the stock is currently owned by company insiders.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.